Emerging drugs for acute lymphocytic leukemia

Expert Opinion on Emerging Drugs

Volumn 19, Issue 1, 2014, Pages 37-50

  Mathisen, Michael S ^a   Kantarjian, Hagop M ^a   Jabbour, Elias J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Blinatumomab; Inotuzumab; Monoclonal antibodies

Indexed keywords

ALISERTIB; ANTHRACYCLINE; ANTILEUKEMIC AGENT; ASPARAGINASE; BLINATUMOMAB; BRENTUXIMAB VEDOTIN; CLOFARABINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FORODESINE; HYDROCORTISONE; IMATINIB; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; NELARABINE; NILOTINIB; PONATINIB; PREDNISONE; RITUXIMAB; UNINDEXED DRUG; VINCRISTINE; VINCRISTINE SULFATE; VORINOSTAT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; B CELL LYMPHOMA; B LYMPHOCYTE; BLOOD CELL COUNT; BONE MARROW EXAMINATION; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL DIVISION; CELL SURFACE; CELLS; CENTRAL NERVOUS SYSTEM DISEASE; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; CLASSICAL HODGKIN LYMPHOMA; COMORBIDITY; CONFUSION; CONTINUOUS INFUSION; CYTOKINE RELEASE SYNDROME; DNA SYNTHESIS; FEBRILE NEUTROPENIA; FEVER; FLOW CYTOMETRY; FOLLOW UP; HEADACHE; HEALTH CARE QUALITY; HEART ARREST; HEMATOLOGIC MALIGNANCY; HISTONE MODIFICATION; HUMAN; HYPERTRANSAMINASEMIA; INCIDENCE; INDUCTION CHEMOTHERAPY; INTRAOCULAR LYMPHOMA; LARGE CELL LYMPHOMA; LEUKEMIA CELL; LEUKEMIA CELL LINE; LEUKEMIA RELAPSE; LIVER FUNCTION TEST; LIVER TOXICITY; LONG TERM SURVIVAL; LYMPHOMA; MORBIDITY; NEUROTOXICITY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYMERASE CHAIN REACTION; POPULATION; PRE T LYMPHOCYTE; RECURRENCE FREE SURVIVAL; REVIEW; RISK FACTOR; SALVAGE THERAPY; SEIZURE; SOMATIC MUTATION; SURVIVAL RATE; T LYMPHOCYTE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT FAILURE; VEIN OCCLUSION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84896699268     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2014.872629     Document Type: Review

References (95)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11-30
2. National Cancer Institute. SEER Stat Fact Sheet: acute Lymphocytic Leukemia. Bethesda. 2012. Available from: http://seer.cancer.gov/statfacts/html/ alyl. html
3. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010;2010:7-12
4. Pui CH, Campana D, Pei D, et al. Treating childhood leukemia without cranial irradiation. N Engl J Med 2009;360:2730-41
5. Freireich EJ. The history of leukemia therapy-a personal journey. Clin Lymphoma Myeloma Leuk 2012;12:386-92
6. Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 2012;120:1165-74
7. Alvarnas JC, Brown PA, Aoun P, et al. NCCN clinical practice guidelines in oncology: acute lymphoblastic leukemia. Version 1.2013 Available from: www. NCCN.org
8. Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood 1999;93(11):3983-93
9. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354(2):166-78
10. Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study-Dana Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol 2013;31(9):1202-10
11. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper- CVAD, a dose-intensive regimen, in adult acute lymphoblastic leukemia. J Clin Oncol 2000;18(3):547-61
12. Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010;28:3880-9
13. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a doseintensive regimen, in adult acute lymphocytic leukemia. Cancer 2004;101(12):2788-801
14. Hoelzer D, Huettmann A, Kaul F, et al. Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high-risk patients; results of 263 CD20+ patients studied prospectively in GMALL study 07/2003. Blood (ASH Annual Meeting Abstracts) 2010;116:abstract 170
15. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1,500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005;106(12):3760-7
16. Stock W. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010;2010:21-9
17. Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009;27:911-18
18. Nachman JB, La MK, Hunger SP, et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the Children's Oncology Group. J Clin Oncol 2009;27(31):5189-94
19. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood 2002;100:2357-66
20. Thomas DA, O'Brien SM, Faderl S, et al. Long-term outcome after hyper- CVA and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL) [abstract 6506]. J Clin Oncol 2010;28:15s
21. Tanguy-Schmidt A, Rousselot P, Chalandon Y, et al. Long-term follow up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biol Blood Marrow Transplant 2013;19:150-5
22. Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosomepositive acute lymphoblastic leukemia: northern Italy Leukemia Group protocol 09/00. J Clin Oncol 2010;28:3644-52
23. Fielding AK, Buck G, Lazarus HM, et al. Imatinib significantly enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia; final results of the UKALLXII/ECOG2993 trial. Blood (ASH Annual Meeting Abstracts) 2010;116:abstract 169
24. Pfeifer H, Goekbuget N, Volp C, et al. Long-term outcome of 335 patients receiving different schedules of imatinib and chemotherapy as front-line treatment for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood (ASH Annual Meeting Abstracts) 2010;116:abstract 173
25. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119:1123-9
26. Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9
27. Hu Y, Liu Y, Pelletier S, et al. Requirement of SRC kinases Lyn, Hck and Fgr for BCR-ABL1-induced Blymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004;36:453-61
28. Ravandi F, O'Brien S, Thomas D, et al. First report of phase II study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 2010;116:2070-7
29. Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood 2013;122(7):1214-21
30. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia (ALL) the greatest benefit is achieved from a matched sibling allogeneic transplant in first complete remission (CR) and an autologous transplant is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the international ALL trial (MRC UKALL XII/ECOG 2993). Blood 2008;111:1827-33
31. Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004;22(20):4075-86
32. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): an MRC UKALL12/ECOG2993 study. Blood 2007;109:944-50
33. Kantarjian HM, Thomas D, Ravandi F, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 2010;116:5568-74
34. Faderl S, Thomas DA, O'Brien S, et al. Augmented hyper-CVAD based on doseintensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk 2011;11:54-9
35. Clolar (clofarabine) Package Insert. Genzyme Corp; Cambridge, MA; 2012
36. Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 2011;118:6043-9
37. Pigneaux A, Sauvezie M, Vey N, et al. Clofarabine combinations in adults with refractory/relapsed acute lymphoblastic leukemia (ALL): a GRAAL report. Blood (ASH Annual Meeting Abstracts) 2011;118:abstract 2586
38. Barba P, Sampol A, Calbacho M, et al. Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma: the Spanish experience. Am J Hematol 2012;87:631-4
39. Arranon (nelarabine) Package Insert. GlaxoSmithKline; Research Triangle Park, NC 2011
40. Gokbuget N, Basara N, Baurmann H, et al. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood 2011;118:3504-11
41. Clinicaltrials.gov (Web site). Pharmacokinetic and pharmacodynamics study of nelarabine in patients with relapsed/refractory lymphoid malignancies. Available from: www. clinicaltrials.gov (NCT01094860) [Last accessed 10 October 2013]
42. Jain P, Kantarjian HM, Thomas DA, et al. Phase II study of nelarabine with Hyper-CVAD in patients with previously untreated T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LL). Blood (ASH Annual Meeting Abstracts) 2012;120:abstract1501
43. O'Brien S, Schiller G, Lister J, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol 2013;31(6):676-83
44. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346(4):235-42
45. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376(9747):1164-74
46. Firer MA, Gellerman G. Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol 2012;5:70
47. Bross PF, Beltz J, Chen XH, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001;7(6):1490-6
48. Rowe JM, Lowenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood 2013;121(24):4838-41
49. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30(18):2190-6
50. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30(18):2183-9
51. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009;10(2):147-56
52. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012;481(7380):157-63
53. Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012;22(2):153-66
54. Quintas-Cardama A, Tong W, Manshouri T, et al. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T-cell malignancies. Leukemia 2008;22(6):1117-24
55. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23(6):1054-61
56. Kantarjian H, O'Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012;119(9):1981-7
57. Jabbour E, Branford S, Saglio G, et al. Practical advice for determining the role of BCR-ABL mutations in guiding tyroside kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 2011;117(9):1800-11
58. Gibbons DL, Pricl S, Kantarjian H, et al. The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer 2012;118(2):293-9
59. Rousselot P, Coude MM, Huguet F, et al. Dasatinib and low intensity chemotherapy for first-line treatment in patients with de novo Philadelphia positive ALL aged 55 and over: final results of the EWALL-Ph-01 study. Blood (ASH Annual Meeting Abstracts) 2012;120:abstract 666
60. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16:401-12
61. Iclusig (ponatinib) Package Insert. ARIAD Pharmaceuticals; Cambridge, MA; 2012
62. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012;367:2075-88
63. Jabbour E, Kantarjian HM, Thomas DA, et al. Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. J Clin Oncol 2013;31(Suppl):abstract 7024
64. Farag SS. The potential role of Aurora kinase inhibitors in haematological malignancies. Br J Haematol 2011;155(5):561-79
65. Green MR, Woolery JE, Mahadevan D. Update on Aurora kinase targeted therapeutics in oncology. Expert Opin Drug Discov 2011;6(3):291-307
66. Muscal JA, Scorsone KA, Zhang L, et al. Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Invest New Drugs 2013;31(1):39-45
67. Clinicaltrials.gov (Web site). Alisertib in treating young patients with recurrent or refractory solid tumors or leukemia. Available from: www.clinicaltrials.gov (NCT01154816) [Last accessed 10 October 2013]
68. Giblett ER, Ammann AJ, Wara DW, et al. Nucleoside phosphorylase deficiency in a child with severely defective T-cell immunity and normal Bcell immunity. Lancet 1975;1:1010-13
69. Robak P, Robak T. Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treat Rev 2013;39(8):851-61
70. Gandhi V, Kilpatrick JM, Plunkett W, et al. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood 2005;106(13):4253-60
71. Clinicaltrials.gov (Web site). Forodesine hydrochloride (BCX-1777) for B-cell acute lymphoblastic leukemia. Available from: www.clinicaltrials.gov (NCT00289562) [Last accessed 10 October 2013]
72. Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007;25(11):1350-6
73. Clinicaltrials.gov (Web site). Intrathecal rituximab in lymphoid malignancies involving the central nervous system. Available from: www.clinicaltrials.gov (NCT01596127) [Last accessed 9 October 2013]
74. Arzerra (ofatumumab) Package Insert. GlaxoSmithKline; Research Triangle Park, NC; 2011
75. Wierda WG, Padmanabhan S, Chan GW, et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase II international study. Blood 2011;118:5126-9
76. Clinicaltrials.gov (Web site). HyperCVAD plus ofatumumab in CD- 20 positive acute lymphoblastic leukemia. Available from: www.clinicaltrials.gov (NCT01363128)
77. Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma 1995;18:385-97
78. Blanc V, Bousseau A, Caron A, et al. SAR3419: an anti-CD19-maytansinoid immunoconjugate for the treatment of Bcell malignancies. Clin Cancer Res 2011;17(20):6448-58
79. Chu YW, Polson A. Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia. Future Oncol 2013;9(3):355-68
80. Widdison WC, Wilhelm SD, Cavanagh EE, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 2006;49:4392-408
81. Younes A, Kim S, Romaguera J, et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol 2012;30:2776-82
82. Clinicaltrials.gov [Web site]. SAR3419 in acute lymphoblastic leukemia. Available from: www.clinicaltrials.gov (NCT01440179) [Last accessed 18 February 2013]
83. Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: a historical perspective. Pharmacol Ther 2012;136:334-42
84. Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29:2493-8
85. Topp MS, Gokbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120:5185-7
86. Topp M, Gokbuget N, Zugmaier G, et al. Effect of anti-CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed/refractory B-precursor ALL. J Clin Oncol 2012;30:abstract 6500
87. Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group pilot study. J Clin Oncol 2008;26:3756-62
88. Advani A, McDonough S, Coutre S, et al. Southwest Oncology Group Study S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 2012;120:abstract 2603
89. Sharkey RM, Govindan SV, Cardillo TM, Goldenberg DM. Epratuzumab-SN-38: a new antibodydrug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther 2012;11:224-34
90. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calicheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 2012;13:403-11
91. Kebriaei P, Wilhelm K, Ravandi F, et al. Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk 2013;Epub ahead of print
92. Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 2013;119(15):2728-36
93. Clinicaltrials.gov (Web site). Inotuzumab ozogamicin in elderly acute lymphoblastic leukemia. Available from: www.clinicaltrials.gov (NCT01371630) [Last accessed 10 October 2013]
94. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365(8):725-33
95. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368(16):1509-18